Biohaven logo

Biohaven

BHVN | NYSE
Chart Builder DCF Calculator
$13.80
-$0.02 (-0.14%)
At close: Nov 16, 2026, 4:00 PM ET
$13.90
+$0.10 (+0.72%)
After-hours: Nov 16, 2026, 6:54 PM ET
-0.14%

Rating

Updated: Nov 16, 2026
32.8
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #718/1021 (Top 70%)

Key Statistics

Market Data

Market Cap $2.08B
1D Range
13.70 14.20
52W Range
8.09 16.95

Valuation (TTM)

PE -3.58
PB -21.22
EV/EBITDA -4.18

Valuation (NTM)

Forward PE N/A
Forward PEG 0.06
Price Target $20.00
Loading financial charts...

Profile

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develo...

Sector Healthcare
Industry Biotechnology
Employees 274
IPO Date Sep 23, 2022
Fiscal Year January - December

Latest News

Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results

18 days ago · prnewswire.com

Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results
Biohaven Stock Heads for Best Day in 3 Years as FDA Agrees to Review Drug Again

26 days ago · barrons.com

Biohaven Stock Heads for Best Day in 3 Years as FDA Agrees to Review Drug Again
Biohaven Rebounds With FDA Review Date for Rare Disease Drug

26 days ago · benzinga.com

Biohaven Rebounds With FDA Review Date for Rare Disease Drug
Biohaven Expands Asian Licensing Footprint Through Strategic Ono Agreement

1 month ago · benzinga.com

Biohaven Expands Asian Licensing Footprint Through Strategic Ono Agreement
Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease

1 month ago · gurufocus.com

Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease
Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026

2 months ago · gurufocus.com

Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026
Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)

2 months ago · prnewswire.com

Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)
Biohaven Stock Is Sinking. Epilepsy Drug Trial Roadblock Is Only the Latest Blow.

2 months ago · barrons.com

Biohaven Stock Is Sinking. Epilepsy Drug Trial Roadblock Is Only the Latest Blow.
FDA Pauses New Enrollment for Biohaven Epilepsy Drug Program

2 months ago · benzinga.com

FDA Pauses New Enrollment for Biohaven Epilepsy Drug Program
US FDA pauses new enrollment in Biohaven's epilepsy drug trials

2 months ago · reuters.com

US FDA pauses new enrollment in Biohaven's epilepsy drug trials

Earnings

Next Earnings
Mar 1, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
10
Consensus
Buy
Price Target
$20.00
Upside
+44.93%
Buy (6)
Hold (3)
Sell (1)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.